Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy
The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Primary Sponsor
The University of Sydney
Collaborating Groups
Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
Closing Date of Accrual
30 June 2019
Trial Chairperson
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
Trial Contact
nivorad@ctc.usyd.edu.au
Related Post
26 August, 2025
Welcome to new TROG committee members and thank you to long-serving members
LATEST NEWS: 26 August 2025 The TROG Scientific Committee
12 August, 2025
TROG 15.03/ANZUP 16001 FASTRACK II: economic analysis shows new technique is cheaper and more effective in the Australian setting
TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer